Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Wesley Buckingham"'
Autor:
Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen, Pernille Wehn, Tressa Hood, Namratha Ram, Wesley Buckingham, Sean Ferree, Bent Ejlertsen
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophospham
Externí odkaz:
https://doaj.org/article/4673ff5f6aca4466993ba61ac60353e3
Autor:
Emilio Alba, Vicente Peg, Santiago Ramón y Cajal, Barbara Adamo, Nuria Ribelles, Sean Ferree, Paolo Nuciforo, Catherine Ellis, Sherley Díaz, Martina Álvarez, Maria Vidal, Carl Schaper, H. Arthur Jeiranian, Wesley Buckingham, Begoña Jimenez, Patricia Galván, Aleix Prat
Purpose: Most hormone receptor (HR)+/HER2− breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those patients who are likely to benefit. Using the Prosigna assay, we first evaluated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ea2a853b16cd47b00ec60ed58d36a9
https://doi.org/10.1158/1078-0432.c.6524927.v1
https://doi.org/10.1158/1078-0432.c.6524927.v1
Autor:
Emilio Alba, Vicente Peg, Santiago Ramón y Cajal, Barbara Adamo, Nuria Ribelles, Sean Ferree, Paolo Nuciforo, Catherine Ellis, Sherley Díaz, Martina Álvarez, Maria Vidal, Carl Schaper, H. Arthur Jeiranian, Wesley Buckingham, Begoña Jimenez, Patricia Galván, Aleix Prat
Supplementary Figure S1 and Supplementary Tables S1-S2. Supplementary Figure S1. Diagram of tissue block usage for CNB Development Study and Chemo-prediction Validation Study. Supplemental Table S1. Top-10 and bottom-10 Prosigna gene-correlations bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e5115285ec536c3b39df7483a03db5
https://doi.org/10.1158/1078-0432.22461854.v1
https://doi.org/10.1158/1078-0432.22461854.v1
Autor:
Wesley Buckingham, Anne Roslind, Sean Ferree, Maj-Britt Jensen, Bent Ejlertsen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen
Publikováno v:
Clinical Breast Cancer. 20:e423-e432
Purpose The Prosigna-PAM50 risk of recurrence (ROR) score has documented clinical utility for the prediction of 10-year distant recurrence (DR). The present study investigated the value of Prosigna-PAM50 for predicting 10-year DR and overall survival
Autor:
Jeanette Dupont Jensen, Torsten O. Nielsen, Eva Balslev, Ann Knoop, Wesley Buckingham, Anne-Vibeke Lænkholm, Maj-Britt Jensen, Sean Ferree, Vesna Glavicic, Henning T. Mouridsen, Bent Ejlertsen, Dorte Nielsen
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-9 (2020)
Jensen, M B, Lænkholm, A V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
Jensen, M-B, Lænkholm, A-V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
NPJ Breast Cancer
Jensen, M B, Lænkholm, A V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
Jensen, M-B, Lænkholm, A-V, Balslev, E, Buckingham, W, Ferree, S, Glavicic, V, Dupont Jensen, J, Søegaard Knoop, A, Mouridsen, H T, Nielsen, D, Nielsen, T O & Ejlertsen, B 2020, ' The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients ', npj Breast Cancer, vol. 6, 7 . https://doi.org/10.1038/s41523-020-0148-0
NPJ Breast Cancer
The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access
Autor:
Wesley Buckingham, Maj-Britt Jensen, Bent Ejlertsen, Anne Vibeke Lænkholm, Sean Ferree, Torsten O. Nielsen, Jens Ole Eriksen
Publikováno v:
Acta Oncologica. 57:44-50
The Prosigna-PAM50 risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR) in hormone receptor-positive breast cancer. Here, we examine the ability of Prosigna for predicting DR at 10
Autor:
Wesley Buckingham, M.B. Jensen, AS Knoop, T Kiboel, Carl Schaper, Jens Ole Eriksen, B. B. Rasmussen, A-V Lænkholm, Taryn Haffner, Sean Ferree, Bent Ejlertsen
Publikováno v:
Cancer Research. 77:P1-07
Background: The Prosigna (PAM50) risk of recurrence (ROR) score predicts 10yr DR in early breast cancer patients treated with ET alone (level 1 evidence). Invasive lobular breast cancer (ILBC) accounts for 10-15% of all breast cancer histological sub
Autor:
Wesley Buckingham, Mitchell Dowsett, Ivana Sestak, Sean Ferree, Jack Cuzick, Itay Israel Shemesh
Publikováno v:
Cancer Research. 80:P5-06
Background: Several multigene assays are available for managing ER-positive, HER2-negative early stage breast cancer but with little direct comparative information within this patient population. Existing evidence suggests that current multigene assa
Autor:
Wesley Buckingham, I. Rodrigo, Cesar E. Ramirez, Carl Schaper, Luis Vicioso, V. de Luque, Ester Villar, Emiliano Zamora de Alba, C González-Hermoso, Naeem Dowidar, M José Lozano, Nuria Ribelles, P. Sanchez Rovira, Begoña Jiménez-Rodríguez, R Chica Parrado, Ana Inés Fernández, Aleix Prat, M. Alvarez, Sean Ferree, Arthur Jeiranian, Irene Zarcos
Publikováno v:
Cancer Research. 76:P3-07
Background: Prosigna's ROR score was demonstrated as a strong predictor of response to NAC in a representative cohort of EBC patients including HR+/HER2- N0-N1 patients.1 Given that the ROR score is partially derived from the correlation of the tumor
Autor:
A-V Lænkholm, Wesley Buckingham, B Bruun Rasmussen, J Ole Eriksen, AS Knoop, Taryn Haffner, Carl Schaper, Torben Kiboll, M.B. Jensen, Bent Ejlertsen, Sean Ferree
Publikováno v:
Cancer Research. 76:P2-08
Background: HR+EBC patients are routinely treated with both adjuvant radiation therapy (RT) and ET. RT is considered an important tool for achieving local control of disease. A limited number of biomarkers have been demonstrated to predict LR. In a p